Dr. Reddys Laboratories Ltd has launched Celadrin, a product that helps reduce pain and inflammation in patients with osteoarthritis and other joint related problems, through an alliance with Cymbiotics (USA). Celadrin was developed by Imagenetix (IAGX), USA, and is licensed to Cymbiotics Inc.

Commenting on the launch, Satish Reddy, managing director and COO, of the Company said, "Dr. Reddy's is emerging as the 'partner of choice' for many innovators in health care on account of our strong brand equity and extensive reach in the Indian market. Celadrin will enhance the treatment options available to medical practitioners in India."

Celadrin contains a proprietary complex of Cetylated Fatty Acid Esters and Omega-3 fatty acids (EPA and DHA) that can be safely used in the treatment of arthritis.

The product will be available as capsules and cream (30 gm tube).